ライフサイエンスコーパス: claudication

1 ambulation, which is known as "intermittent claudication".

2 patency rates of nearly 80% in patients with claudication.

3 %, and 0.5%, respectively, for patients with claudication.

4 eral arterial disease (PAD) and intermittent claudication.

5 ons militate against active intervention for claudication.

6 lity of life [QOL] in patients with arterial claudication.

7 ulceration or amputation, and improvement of claudication.

8 schemic events in patients with intermittent claudication.

9 re, stroke, incident angina, or intermittent claudication.

10 ife, and determined the prevalence of venous claudication.

11 sical activity in patients with intermittent claudication.

12 ng performance in patients with intermittent claudication.

13 alvage, as well as those being evaluated for claudication.

14 has some effect on dementia and intermittent claudication.

15 15 patients (20 limbs) evaluated because of claudication.

16 atients with moderate-to-severe intermittent claudication.

17 peripheral arterial disease had intermittent claudication.

18 eral arterial disease (PVD) and intermittent claudication.

19 sed for patients with disabling intermittent claudication.

20 tolerated for the treatment of intermittent claudication.

21 nt of stable, moderately severe intermittent claudication.

22 ble treatment for patients with intermittent claudication.

23 dity, including the symptoms of intermittent claudication.

24 e common in the population than intermittent claudication.

25 who have exertional leg symptoms other than claudication.

26 are not consistent with classic intermittent claudication.

27 d as a first-line treatment for intermittent claudication.

28 f their limb symptoms of classic or atypical claudication.

29 e role for revascularization in intermittent claudication.

30 prove mobility in patients with intermittent claudication.

31 ocyte adhesion in patients with intermittent claudication.

32 ear in unselected patients with intermittent claudication.

33 was found for patients with the diagnosis of claudication.

34 t may warrant further study in patients with claudication.

35 nd December 2009 for the purpose of treating claudication.

36 ive treatment for patients with intermittent claudication.

37 h peripheral artery disease and intermittent claudication.

38 uality of life in patients with intermittent claudication.

39 D participants with and without intermittent claudication.

40 ascular events in patients with intermittent claudication?

41 of 579 lesions were treated in 275 patients (claudication 101 patients (36.7%) and critical limb isch

42 PVI than for LEB in patients presenting with claudication (12.3+/-2.7% and 19.0+/-3.5% at 1 and 3 yea

43 Among patients with intermittent claudication, 24-week treatment with ramipril resulted i

44 were asymptomatic, 22% were associated with claudication, 3% were associated with rest pain, and 1%

45 ventions between 2001 and 2006 performed for claudication (46.3%) or limb-threatening ischemia (52.7%

46 senting limbs (mean patient age 66.4 yo; 43% claudication, 57% limb-threatening ischemia), 107 were t

47 Among patients with intermittent claudication after 1 year of follow-up, a combination th

48 al artery disease patients with intermittent claudication after a home-based exercise program, a supe

49 Compared with participants with intermittent claudication, always asymptomatic PAD participants had s

50 tics compared with persons with intermittent claudication and a sedentary, asymptomatic, age-matched

51 ing PAD at baseline if they had intermittent claudication and an ankle brachial index of <0.85, or if

52 ral artery disease (n=3787) had a history of claudication and an ankle-brachial index of <0.85 or pri

53 ctive endovascular therapy for patients with claudication and CLI with a low mortality, low complicat

54 of LEB and PVI in patients with symptomatic claudication and critical limb ischemia.

55 A total of 82 patients with claudication and infrainguinal peripheral artery disease

56 is not useful in patients with intermittent claudication and PAD.

57 he observed association between intermittent claudication and rhinitis.

58 nd secondary branches of the aorta may cause claudication and tissue gangrene, whereas aortitis may l

59 and prolong walking distance for those with claudication and to reduce amputation rates among those

60 e were associated with an increased risk for claudication and were included in the profile.

61 troke), and 3) peripheral vascular (arterial claudication and/or gangrene or significant tissue loss

62 according to the presence or absence of jaw claudication and/or visual abnormalities, fever, concomi

63 dence of ischemic symptoms, indicated by jaw claudication and/or visual symptoms, typically expressed

64 patients was 0.71, 76.6% of the patients had claudication, and 4.6% had critical limb ischemia.

65 ions of GCA, such as ocular involvement, jaw claudication, and aortic arch syndrome.

66 rtality, total cardiovascular disease (CVD), claudication, and congestive heart failure (CHF).

67 At 1 year, patients were asymptomatic for claudication, and duplex assessment demonstrated lack of

68 nosis or occlusion, symptoms of intermittent claudication, and maximum walking distance of > or = 30

69 an clinical trials as treatments for angina, claudication, and stroke.

70 ng in skeletal muscle ischemia, intermittent claudication, and, in more severe stages of disease, lim

71 tion; 5% angina pectoris; 2.3%, intermittent claudication; and 7%, a carotid bruit.

72 In patients with intermittent claudication, antiplatelet therapies are associated with

73 therapy in patients with lifestyle-limiting claudication are often underutilized before referral for

74 ed at regular examinations, new intermittent claudication assessed by annual surveillance, or PAD-rel

75 ion, coronary insufficiency, angina, stroke, claudication) at 50 years of age.

76 allel-design study included 354 persons with claudication attributable to peripheral arterial disease

77 ial in patients with atherosclerotic PVD and claudication, bFGF was well-tolerated.

78 e most common symptom of PAD is intermittent claudication, but noninvasive measures, such as the ankl

79 Many patients with claudication can be treated by exercise and medical ther

80 Patients with intermittent claudication carry a high risk for cardiovascular compli

81 190 patients with intermittent claudication caused by infra-inguinal atherosclerosis we

82 Intermittent claudication causes pain on walking, has no tissue loss,

83 of those with prior I-FDVT developed venous claudication compelling interruption of walking in 15.4%

84 ated to the 3 main clinical presentations of claudication, critical limb ischemia, and acute limb isc

85 Both groups were encouraged to walk to claudication daily.

86 alation trial was conducted in patients with claudication demonstrating ankle/brachial index <0.8.

87 riteria included age > or =40 years, initial claudication distance (ICD) on treadmill (12.5% incline,

88 lth-related quality of life and intermittent claudication distance after 1 year in patients with stab

89 t was the change at 6 months in the absolute claudication distance as assessed by the Skinner-Gardner

90 Although absolute claudication distance improved in both L-arginine- and p

91 Intermittent claudication distance improved significantly in the inva

92 ed ICD and maximum distance walked (absolute claudication distance, or ACD).

93 o determine initial (ICD) and absolute (ACD) claudication distances, and quality of life assessment (

94 r age, sex, initial [ICD] and absolute [ACD] claudication distances, pressure indices [ABI], poplitea

95 r 6 months in 133 subjects with intermittent claudication due to PAD in a single-center setting.

96 Intermittent claudication due to peripheral arterial occlusive diseas

97 th unilateral exercise-limiting intermittent claudication during 2 qualifying treadmill tests, with p

98 h can occur in the condition of intermittent claudication during exertion, an exaggerated vasoconstri

99 The durability of claudication exercise interventions merits its considera

100 Patients with claudication experience significant disability, owing to

101 d to compute the probability of intermittent claudication for specified levels of risk factors.

102 tients with advanced CVD (CEAP3-6 +/- venous claudication) for chronic obliteration of the I-F (+/-IV

103 followed 255 male patients with intermittent claudication from the CAVASIC Study during 7 years for o

104 oronary artery bypass graft surgery, stroke, claudication, gangrene, or tissue loss and/or peripheral

105 arterial disease (PAD) without intermittent claudication have been established as beneficial.

106 Current treatment strategies for claudication have limitations.

107 index, diabetes mellitus, sex, intermittent claudication, heart rate, estimated glomerular filtratio

108 etween respiratory diseases and intermittent claudication (i.e. pain in the leg during walking that d

109 se patients included those with intermittent claudication (IC) (n = 23) and critical limb ischemia (C

110 but it remains unclear whether intermittent claudication (IC) incidence and mortality rates have cha

111 Intermittent claudication (IC) is associated with an increased risk o

112 Importance: Intermittent claudication (IC) is the most common presentation of inf

113 or have leg symptoms other than intermittent claudication (IC).

114 Intermittent claudication identifies persons at increased risk for de

115 Indications for stent placement were claudication in 312 (62%), rest pain in 107 (21%), ulcer

116 reatment to improve symptoms of intermittent claudication in patients with PAD.

117 taglandin I(2) analogue, in the treatment of claudication in patients with peripheral arterial diseas

118 The prevalence of intermittent claudication in these groups was, respectively, 2.5%, 3.

119 PACE (Patients With Intermittent Claudication Injected With ALDH Bright Cells) is a Natio

120 95% CI, 27-60%) of patients developed venous claudication ipsilateral to I-FDVT (ICD: 130 m, range 10

121 Claudication is a common and disabling symptom of periph

122 r invasive revascularization in intermittent claudication is low or very low.

123 Intermittent claudication is relatively common in elderly patients an

124 s of peripheral artery disease, intermittent claudication, leg revascularisation, and leg amputation)

125 ted with the age of the patients but not the claudication-limited exercise performance of the patient

126 in peripheral arterial disease patients with claudication-limited exercise performance.

127 isease (PAD) have exercise limitation due to claudication-limited pain and metabolic alterations in s

128 al limb ischemia (CLI) or lifestyle-limiting claudication (LLC).

129 Absence of neurogenic claudication (LR, 0.23; 95% CI, 0.17-0.31) decreased the

130 in (LR, 6.3; 95% CI, 3.1-13), and neurogenic claudication (LR, 3.7; 95% CI, 2.9-4.8).

131 undred sixty-five patients with intermittent claudication (mean, 65.3 [SD, 6.7] years) were administe

132 gh adherence and is efficacious in improving claudication measures similar to a standard supervised e

133 Patients with intermittent claudication (n = 897) were randomized to receive either

134 , worsening hypertension (n=1), intermittent claudication (n=1) and wound infection (n=1).

135 to leg symptom groups including intermittent claudication (n=215) and always asymptomatic (participan

136 , Clinical Modification, diagnosis codes for claudication (N=8128), rest pain (N=3056), and ulceratio

137 ith PAD have neither classic symptoms of leg claudication nor threatened limbs but have an extraordin

138 d complicated CVD (C3-C6) ameliorates venous claudication, normalizes outflow, and enhances calf musc

139 Incapacitating venous claudication noted in 62.5% (10 of 16, 95% CI, 35.8%-89.

140 Intermittent claudication occurred in a total of 381 men and women.

141 Both exercise programs increased claudication onset time (P<0.001) and peak walking time

142 Primary outcome measures included claudication onset time and peak walking time obtained f

143 The changes in claudication onset time and peak walking time were simil

144 Secondary end points included changes in claudication onset time and quality of life, assessed wi

145 ly significant improvements in the treadmill claudication onset time as compared with placebo.

146 Improvement in claudication onset time was greater for SE compared with

147 s, including DeltaPWT, ankle-brachial index, claudication onset time, and quality-of-life measures (S

148 The secondary end point was change in claudication onset time, and tertiary end points include

149 There were no significant differences in claudication onset time, ankle-brachial index, or qualit

150 s in the ABI, WIQ distance and speed scores, claudication onset time, or mental or physical component

151 Peak walking time, claudication onset time, Walking Impairment Questionnair

152 , 476 patients with symptomatic intermittent claudication or ischemic pain while at rest and angiogra

153 rial in which 331 patients with intermittent claudication or ischemic rest pain attributable to super

154 ntly developed symptomatic PAD (intermittent claudication or need for revascularization) and in an eq

155 pheral arterial disease than is intermittent claudication or other leg symptoms.

156 One hundred two patients with claudication or rest pain were randomly assigned 1:1 to

157 ts were defined as bypass, major amputation, claudication, or percutaneous angioplasty.

158 mary end point event or angina, intermittent claudication, or transient ischemic attack; and (2) all-

159 s were directly related to the prevalence of claudication (p = 0.001) and aortic aneurysm (p = 0.02).

160 oncalf pain, atypical calf pain, and classic claudication (P=0.002).

161 compared with nonusers for the diagnosis of claudication (P=0.003), a similar trend for rest pain (P

162 mented response occurred before the onset of claudication pain and was attenuated by approximately 50

163 ed of intermittent walking to nearly maximal claudication pain for 12 weeks.

164 al arterial disease include pain on walking (claudication), pain at rest, and loss of tissue integrit

165 ral artery disease and to explore associated claudication physiological mechanisms.

166 The classic manifestations are headache, jaw claudication, polymyalgia rheumatica (PMR), and visual s

167 presenting manifestations are headache, jaw claudication, polymyalgia rheumatica, and visual symptom

168 ess fractures, stress reaction, periostitis, claudication, popliteal artery entrapment, and periphera

169 among patients referred for biopsy were jaw claudication (positive likelihood ratio [LR], 4.2; 95% c

170 The San Diego Claudication Questionnaire assessed exertional leg pain.

171 r in patients with stable lifestyle-limiting claudication receiving current medical management.

172 mities) with known or suspected intermittent claudication referred for lower extremity treadmill exer

173 sment, unselected patients with intermittent claudication requesting treatment for claudication were

174 The intermittent claudication risk profile allows physicians to identify

175 am Heart Study, we developed an intermittent claudication risk profile.

176 hout asthma was associated with intermittent claudication (RRR:4.63, 95% CI:1.72-12.5), whereas no si

177 METHODS AND Patients with intermittent claudication secondary to peripheral artery disease who

178 attack or stroke, a history of intermittent claudication, stenosis of 80 to 94 percent of the lumina

179 obasilar insufficiency or,most commonly, arm claudication.Subclavian steal should be considered among

180 uestionnaire (EQ-5D) (score range, 0-1), and Claudication Symptom Instrument (CSI) (score range, 0-4)

181 Previously reported lack of worsening in claudication symptoms over time in patients with PAD may

182 remain the first-line medical therapies for claudication symptoms, and anticoagulants are added to p

183 For claudication symptoms, several newer drugs and the use o

184 in PAD participants with and without classic claudication symptoms.

185 Edema was less common in patients with claudication than in those with pain at rest (P = 0.016)

186 is most often manifested by mild symptoms of claudication that can be managed conservatively.

187 aim to enroll 320 patients with intermittent claudication that does not respond to medical management

188 Treatment for claudication that is due to aortoiliac peripheral artery

189 pheral arterial disease include intermittent claudication, that is, pain with walking, and critical l

190 Progression from claudication to limb ischemia is infrequent.

191 Claudication treatment is increasingly being measured by

192 ns merits its consideration as a primary PAD claudication treatment.

193 haracteristic findings include headache, jaw claudication, visual loss, and constitutional symptoms (

194 The presence of venous claudication was assessed by > or =3 independent examine

195 NM-702 used for 24 weeks by patients with claudication was associated with improvements in laborat

196 Among patients with PAD, classic claudication was distinctly uncommon (11%).

197 or cardiovascular prevention and symptoms of claudication was low: any antiplatelet therapy in 35.7%

198 % male, 37% with diabetes) with intermittent claudication were enrolled at medical centers affiliated

199 Two hundred eighty-nine patients with claudication were randomized in a double-blind manner to

200 ittent claudication requesting treatment for claudication were randomly assigned to invasive (n=79) o

201 may be considered for selected patients with claudication who fail endovascular therapy or are not ca

202 peripheral artery disease with intermittent claudication who have not responded to medical treatment

203 lasty, limb or foot amputation, intermittent claudication with objective evidence of peripheral arter

204 lking ability and pressure indices in stable claudication, with a durable outcome.

205 heral artery disease experience intermittent claudication, with consequent loss of quality of life.